Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 9.20% is 46% below its 5-year average of 16.93%, near the low end of its 5-year range (8.20%–24.22%).
As of the fiscal period ended Tuesday, June 30, 2026. 35.48% below its 12-month average of 14.26%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.20%.
DEBT TO ASSETS RATIO
9.20%
DEBT TO ASSETS RATIO AVG TTM
14.26%
DEBT TO ASSETS RATIO AVG 3Y
22.96%
DEBT TO ASSETS RATIO AVG 5Y
16.93%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-35.48%
CURRENT VS 3Y AVG
-59.93%
CURRENT VS 5Y AVG
-45.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 706 covered companies
CURRENT VS SECTOR MEDIAN
+9098.23%
vs the sector median at left
LifeStance Health Group, Inc.
Market Cap
$4.70B
Debt to Assets Ratio
9.20%
TTM Avg
14.26%
3Y Avg
22.96%
5Y Avg
16.93%
Market Cap
$4.75B
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.65B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.86B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.88B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.92B
Debt to Assets Ratio
0.73%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.44B
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.44B
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeStance Health Group, Inc. (LFST) | $4.70B | 9.20% | 14.26% | 22.96% | 16.93% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.75B | 0.03% | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 0.38% | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.62B | 0.20% | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.86B | 0.00% | N/A | N/A | N/A |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.88B | 0.00% | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.92B | 0.73% | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.44B | 0.64% | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.44B | 0.41% | N/A | N/A | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.38B | 0.01% | N/A | N/A | N/A |
Debt/Assets
9.2%
Debt/Equity
0.14
Current Ratio
1.38
Interest Coverage
2.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 9.20% |
| 2026-03-31 | 9.14% |
| 2025-12-31 | 8.81% |
| 2025-09-30 | 22.04% |
| 2025-06-30 | 22.09% |
| 2025-03-31 | 22.47% |
| 2024-12-31 | 22.90% |
| 2024-09-30 | 23.09% |
| 2024-06-30 | 23.47% |
| 2024-03-31 | 24.01% |
| 2023-12-31 | 24.22% |
| 2023-09-30 | 22.35% |
| 2023-06-30 | 22.93% |
| 2023-03-31 | 21.97% |
| 2022-12-31 | 22.03% |
| 2022-09-30 | 10.71% |
| 2022-06-30 | 10.33% |
| 2022-03-31 | 9.06% |
| 2021-12-31 | 8.24% |
| 2021-09-30 | 8.22% |
| 2021-06-30 | 8.20% |
| 2021-03-31 | 24.11% |
| 2020-12-31 | 23.33% |
